Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.
Intermolecular interactions revisited-Flaws in the fabric and applications to lower-dimensional structures. This project aims to capitalise on recent developments, that have shown that previously accepted theories are deeply flawed, in various applications in fundamental physics and in unsolved problems in biology that involve electromagnetic fields. Interactions driven
by electromagnetic fluctuation forces, and real photon exchange, between molecules will be investigated. The project will inv ....Intermolecular interactions revisited-Flaws in the fabric and applications to lower-dimensional structures. This project aims to capitalise on recent developments, that have shown that previously accepted theories are deeply flawed, in various applications in fundamental physics and in unsolved problems in biology that involve electromagnetic fields. Interactions driven
by electromagnetic fluctuation forces, and real photon exchange, between molecules will be investigated. The project will investigate how dispersion interactions change in mesoscopic pores, in electrolytes, and at finite temperatures. Applications involve
catalysis, molecular formation, and quantum logic. The project also aims to develop a unified theory for energy and charge transfer, relevant for photosynthesis and the way biological molecules transfer information.Read moreRead less
Quantum Mechanics and Planetary Atmospheres. The project will increase the visibility and status of Australian research, by the participation of researchers and students in a wide international collaboration, covering experiments, theory, and computation, which will solve a fundamental research problem that has previously defied understanding. The resulting nitrogen model will be relevant to the important fields of global and planetary atmospheric change, and will find immediate application in t ....Quantum Mechanics and Planetary Atmospheres. The project will increase the visibility and status of Australian research, by the participation of researchers and students in a wide international collaboration, covering experiments, theory, and computation, which will solve a fundamental research problem that has previously defied understanding. The resulting nitrogen model will be relevant to the important fields of global and planetary atmospheric change, and will find immediate application in the analysis of results from the NASA missions, Voyager, Cassini, and (later) New Horizons. In the experimental part of the project, an Australian-first extreme-ultraviolet laser facility will be developed which will provide research opportunities complementary to the Australian Synchrotron.Read moreRead less
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Targeting An Ion Pump In The Malaria Parasite With Multiple Compound Classes
Funder
National Health and Medical Research Council
Funding Amount
$384,686.00
Summary
Large-scale antimalarial drug screening projects have identified three different classes of compound that kill the malaria parasite at extremely low doses and which hold real promise as next-generation antimalarials. Genetic evidence, as well as preliminary data from our own lab, has led us to the hypothesis that all three compound classes exert their antimalarial effect by blocking a molecular ion pump on the parasite surface. The aim of this study is to test this.